301096.SZ
百诚医药
SZSE · M 科研服务 · CN
CNY 48.20
−3.15%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 709.7M | 678.0M | 801.9M | 1.0B | 607.4M |
| Cost of Revenue | 414.4M | 410.2M | 385.1M | 350.7M | 198.2M |
| Gross Profit | 295.3M | 267.8M | 416.9M | 666.7M | 409.2M |
| Operating Expenses | |||||
| R&D Expense | 169.0M | 189.9M | 318.3M | 241.0M | 166.1M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 116.4M | 114.9M | 77.5M | 128.6M | 101.4M |
| Selling & Marketing Expense | 10.1M | 10.2M | 15.0M | 9.7M | 7.8M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 320.4M | 338.2M | 424.8M | 363.8M | 236.0M |
| Cost and Expenses | 734.8M | 748.3M | 809.9M | 714.5M | 434.2M |
| Operating Income (EBIT) | (48.9M) | (89.0M) | (34.4M) | 297.0M | 188.6M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (51.1M) | (91.1M) | (36.1M) | 295.7M | 190.9M |
| Income Tax Expense | 278.0K | (743.4K) | 16.9M | 23.7M | (3.1M) |
| Bottom Line | |||||
| Net Income | (51.4M) | (90.4M) | (52.7M) | 272.0M | 194.2M |
| Earnings from Cont. Ops | (51.4M) | (90.4M) | (52.9M) | 272.0M | 194.0M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (51.4M) | (90.4M) | (52.7M) | 272.0M | 194.2M |
| Per Share | |||||
| Basic EPS | (CN¥0.45) | (CN¥0.83) | (CN¥0.49) | CN¥2.51 | CN¥1.80 |
| Diluted EPS | (CN¥0.45) | (CN¥0.83) | (CN¥0.49) | CN¥2.51 | CN¥1.79 |
| Revenue Per Share | CN¥6.54 | CN¥6.23 | CN¥7.45 | CN¥9.39 | CN¥5.63 |
| Shares | |||||
| Basic Shares Outstanding | 108.5M | 108.9M | 107.6M | 108.4M | 107.9M |
| Diluted Shares Outstanding | 108.5M | 108.9M | 107.6M | 108.4M | 107.9M |
| Profitability Metrics | |||||
| EBITDA | — | 68.5M | 111.3M | 388.8M | 255.9M |
| D&A | — | 157.5M | 145.7M | 91.8M | 67.3M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026